IN2015DN00934A - - Google Patents

Info

Publication number
IN2015DN00934A
IN2015DN00934A IN934DEN2015A IN2015DN00934A IN 2015DN00934 A IN2015DN00934 A IN 2015DN00934A IN 934DEN2015 A IN934DEN2015 A IN 934DEN2015A IN 2015DN00934 A IN2015DN00934 A IN 2015DN00934A
Authority
IN
India
Prior art keywords
subject
msc
prostacyclin
administering
treating
Prior art date
Application number
Other languages
English (en)
Inventor
Roger Jeffs
Thomas Petersen
Roger M Ilagan
Michael Wade
Original Assignee
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Therapeutics Corp filed Critical United Therapeutics Corp
Publication of IN2015DN00934A publication Critical patent/IN2015DN00934A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN934DEN2015 2012-08-01 2013-07-30 IN2015DN00934A (OSRAM)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261678207P 2012-08-01 2012-08-01
US201361750458P 2013-01-09 2013-01-09
PCT/US2013/052695 WO2014022373A1 (en) 2012-08-01 2013-07-30 Treatment of pulmonary arterial hypertension with mesenchymal stem cells

Publications (1)

Publication Number Publication Date
IN2015DN00934A true IN2015DN00934A (OSRAM) 2015-06-12

Family

ID=50028470

Family Applications (1)

Application Number Title Priority Date Filing Date
IN934DEN2015 IN2015DN00934A (OSRAM) 2012-08-01 2013-07-30

Country Status (11)

Country Link
US (2) US10071123B2 (OSRAM)
EP (1) EP2879682B1 (OSRAM)
JP (2) JP6901823B2 (OSRAM)
KR (1) KR102143255B1 (OSRAM)
CN (2) CN104684561A (OSRAM)
AU (2) AU2013296611B2 (OSRAM)
CA (1) CA2880808C (OSRAM)
ES (1) ES2671932T3 (OSRAM)
IL (1) IL237021B (OSRAM)
IN (1) IN2015DN00934A (OSRAM)
WO (1) WO2014022373A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2879684B1 (en) 2012-08-01 2019-01-30 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
CN105358163B (zh) * 2012-12-12 2020-09-11 麦瑟布莱斯特公司 内皮功能障碍和炎症的疾病的治疗
ES2697573T3 (es) * 2013-01-09 2019-01-25 United Therapeutics Corp Tratamiento de la vasculopatía con prostaciclina y células madre mesenquimatosas
EP3712142B1 (en) 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
BR112016009207B1 (pt) 2013-10-25 2022-11-22 Insmed Incorporated Compostos de prostaciclina
CA2967385C (en) 2014-11-18 2023-05-16 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
KR101843634B1 (ko) * 2016-04-15 2018-03-30 사회복지법인 삼성생명공익재단 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 만성폐질환 치료용 조성물
IL262720B2 (en) 2016-05-05 2024-06-01 Liquidia Tech Inc Dry powder treprostinil for the treatment of pulmonary hypertension
KR20190041456A (ko) * 2016-06-17 2019-04-22 유나이티드 쎄러퓨틱스 코포레이션 향상된 효능을 가진 세포외 소포
US10946047B2 (en) 2016-06-17 2021-03-16 United Therapeutics Corporation Extracellular vesicles with enhanced potency
ES2927406T3 (es) * 2016-10-24 2022-11-04 United Therapeutics Corp Potenciación de las propiedades inmunomoduladoras de las MSC mediante treprostinil
WO2018119185A1 (en) * 2016-12-23 2018-06-28 StemBios Technologies, Inc. Use of somatic stem cells for increasing heme oxygenase level
EP3773530A4 (en) * 2018-03-30 2022-03-02 Kaydence Pharma AS RAPID IMPROVEMENT OF VASCULAR DISEASES BY ADMINISTRATION OF VITAMIN K
CA3114681A1 (en) 2018-10-05 2020-04-09 Xenotherapeutics, Inc. Xenotransplantation products and methods
US10883084B2 (en) 2018-10-05 2021-01-05 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same
KR20220002600A (ko) 2019-04-29 2022-01-06 인스메드 인코포레이티드 트레프로스티닐 전구약물의 건조 분말 조성물 및 이의 사용 방법
EP4285915A1 (en) * 2022-06-03 2023-12-06 Medizinische Hochschule Hannover Human mesenchymal stem cell-conditioned medium for use in treatment of chronic heart-lung and vascular diseases, in particular, of pulmonary arterial hypertension (pah)

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089815A (en) 1951-10-11 1963-05-14 Lieb Hans Injectable pharmaceutical preparation, and a method of making same
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4714680B1 (en) 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US4965204A (en) 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US5130144B1 (en) 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
US5026365A (en) 1987-04-29 1991-06-25 The University Of Massachusetts Method and apparatus for therapeutically treating immunological disorders and disease states
US4983393A (en) 1987-07-21 1991-01-08 Maximed Corporation Intra-vaginal device and method for sustained drug release
ES2035317T5 (es) 1987-11-09 1998-03-16 Becton Dickinson Co Metodo para analizar celulas hematopoyeticas en una muestra.
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5071741A (en) 1988-04-18 1991-12-10 Cryolife, Inc. Cryoprotective agent and its use in cryopreservation of cellular matter
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5283058A (en) 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5811094A (en) 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
CA2109085C (en) 1991-04-25 2003-03-11 Keith E. Dionne Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
CA2128527A1 (en) 1992-01-21 1993-07-22 Raymond P. Goodrich, Jr. Method of freezing cells and cell-like materials
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
DE69430824T2 (de) 1993-08-12 2003-01-23 Neurotech S.A., Evry Biokompatible immunoisolatorische Kapseln, die genetisch veränderte Zellen enthalten
US5518878A (en) 1993-09-15 1996-05-21 Organogenesis Inc. Cryopreservation of cultured skin or cornea equivalents with agitation
US5693531A (en) 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
WO1995022316A1 (en) 1994-02-17 1995-08-24 New York Blood Center, Inc. Biologic bioadhesive compositions containing fibrin glue and liposomes, methods of preparation and use
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5580714A (en) 1995-03-08 1996-12-03 Celox Laboratories, Inc. Cryopreservation solution
US5629145A (en) 1995-03-24 1997-05-13 Organ, Inc. Cryopreservation of cell suspensions
US5643192A (en) 1995-04-06 1997-07-01 Hamilton Civic Hospitals Research Development, Inc. Autologous fibrin glue and methods for its preparation and use
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
WO1997021824A2 (en) 1995-12-15 1997-06-19 Systemix, Inc. Method for obtaining retroviral vector supernatant having high transduction efficiency
AU4659697A (en) 1996-10-03 1998-04-24 Regents Of The University Of California, The Cryopreservation of human adult and fetal pancreatic cells and human platelets
PT941116E (pt) 1996-11-01 2005-05-31 Ark Therapeutics Ltd Utilizacao de vegf para o fabrico de um medicamento para o tratamento ou prevencao de hiperplasia da intima e dispositivo de entrega
DE69831957T3 (de) 1997-07-14 2009-07-23 Osiris Therapeutics, Inc. Herzmuskelregenerierung unter verwendung mesenchymaler stammzellen
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
US9585916B2 (en) * 1999-03-26 2017-03-07 Northern Therapeutics Inc. Cell based therapy for the pulmonary system
US6197294B1 (en) 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
US9320829B2 (en) 2000-03-15 2016-04-26 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
EP1296724A1 (en) 2000-06-22 2003-04-02 Sam L. Austin Bioadhesive composition and methods of preparation and use
EP1569717A2 (en) 2002-11-30 2005-09-07 Cardiac Pacemakers, Inc. Method and apparatus for cell and electrical therapy of living tissue
US8765813B2 (en) 2003-12-16 2014-07-01 United Therapeutics Corporation Use of treprostinil to treat and prevent ischemic lesions
JP5265190B2 (ja) 2004-09-24 2013-08-14 メソブラスト，インコーポレーテッド 分化多能性増殖間葉系前駆細胞子孫（ｍｅｍｐ）およびその使用
EP2548569B1 (en) 2005-08-19 2014-01-29 Duke University Stem cell derived paracrine factor h1 for use in reducing cell death in cardiac tissue
US20070065414A1 (en) * 2005-09-16 2007-03-22 Boston Scientific Scimed, Inc. Enhanced delivery of cells
US9175261B2 (en) * 2005-12-16 2015-11-03 DePuy Synthes Products, Inc. Human umbilical cord tissue cells for inhibiting adverse immune response in histocompatibility-mismatched transplantation
US8652201B2 (en) 2006-04-26 2014-02-18 The Cleveland Clinic Foundation Apparatus and method for treating cardiovascular diseases
CA2705450A1 (en) * 2006-04-27 2007-11-08 Cell Therapy Technologies, Inc. Et Al Stem cells for treating lung diseases
WO2008077094A2 (en) * 2006-12-19 2008-06-26 Children's Medical Center Corporation Methods for promoting neovascularization
PL2120977T3 (pl) 2007-02-12 2013-12-31 Anthrogenesis Corp Leczenie chorób zapalnych z zastosowaniem łożyskowych komórek macierzystych
JP2011015609A (ja) 2007-10-30 2011-01-27 Asahikawa Medical College 内皮前駆細胞（ｅｐｃ）の増殖・分化誘導方法
CN102014934B (zh) 2008-02-22 2014-08-20 新加坡科技研究局 间充质干细胞颗粒
SG188305A1 (en) * 2010-08-27 2013-04-30 Univ Miami Bone marrow derived cd271 precursor cells for cardiac repair
PL2663313T3 (pl) 2011-01-13 2019-01-31 SciPharm S.à r.l. Sposób zwiększania wszczepiania hematopoetycznych komórek macierzystych
UA114796C2 (uk) * 2011-09-30 2017-08-10 Блубьод Байо, Інк. Спосіб підвищення ефективності трансдукції
EP2879684B1 (en) 2012-08-01 2019-01-30 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
ES2697573T3 (es) 2013-01-09 2019-01-25 United Therapeutics Corp Tratamiento de la vasculopatía con prostaciclina y células madre mesenquimatosas

Also Published As

Publication number Publication date
CN111803523A (zh) 2020-10-23
KR102143255B1 (ko) 2020-08-10
CA2880808C (en) 2023-01-24
US10071123B2 (en) 2018-09-11
US11666602B2 (en) 2023-06-06
CN104684561A (zh) 2015-06-03
US20150246078A1 (en) 2015-09-03
AU2013296611A1 (en) 2015-03-05
EP2879682A1 (en) 2015-06-10
JP2019123726A (ja) 2019-07-25
US20190008904A1 (en) 2019-01-10
EP2879682B1 (en) 2018-03-21
AU2013296611B2 (en) 2017-11-23
AU2018201231A1 (en) 2018-03-15
ES2671932T3 (es) 2018-06-11
WO2014022373A1 (en) 2014-02-06
EP2879682A4 (en) 2016-03-16
JP2015524437A (ja) 2015-08-24
IL237021B (en) 2018-02-28
CA2880808A1 (en) 2014-02-06
KR20150038162A (ko) 2015-04-08
AU2018201231B2 (en) 2019-12-05
JP6901823B2 (ja) 2021-07-14

Similar Documents

Publication Publication Date Title
IN2015DN00934A (OSRAM)
MX2019008428A (es) Inhibidores de glucosilceramida sintasa.
TN2015000091A1 (en) Glucosylceramide synthase inhibitors
GB201316021D0 (en) Vitamin D composition
WO2014153115A3 (en) Compositions and methods for reprogramming hematopoietic stem cell lineages
MY185016A (en) Progenitor cells of mesodermal lineage
NZ702663A (en) Nuclear transport modulators and uses thereof
BR112015011933A8 (pt) Composições bacterianas sinérgicas e métodos de produção e uso das mesmas
MX2013008212A (es) Derivados de 7-azaindol.
BR112014031424A2 (pt) tratamento de células pluripotentes
GB2503852A (en) Compounds for the treatment of neuropsychiatric disorders
EP4582090A3 (en) Composition comprising pegylated arginine deiminase
IL207310A0 (en) Vaccine compositions
MX2016005824A (es) Metodo de cultivo celular.
MX2015012842A (es) Prodecimiento para preparar inhibidores de la glucosilceramida sintasa.
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
WO2014182653A8 (en) Use of lappaol f to inhibit tumor cell growth
TN2013000368A1 (en) Glucosylceramide synthase inhibitors
LI et al. Effects of trichostatin A on the expression of growth arrest and DNA damage-inducible protein 45 alpha in, proliferation of and apoptosis in a human epithelial carcinoma cell line A431
UA50454U (ru) Способ лечения и профилактики варрооза пчел
UA70205U (ru) Применение растительного препарата трипсидан в качестве лекарственного средства для комплексного лечения постинфекционного астенического синдрома и высокой тревожности у детей школьного возраста в условиях организованных коллективов
UA68348U (en) Cryosurgical apparatus
UA98076C2 (ru) Применение немодифицированных фуллеренов с60 в качестве противоопухолевых агентов в терапии злокачественных новообразований
UA97741C2 (ru) Способ восстановления кожных покровов при глубоких распространенных ожогах микроаутодермотрансплантатами
UA57256U (ru) Способ лечения больных c разлитыми флегмонами челюстно-лицевой области